{
    "clinical_study": {
        "@rank": "97635", 
        "arm_group": [
            {
                "arm_group_label": "Anti-TNFa regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "Etanercept  50 mg"
            }, 
            {
                "arm_group_label": "Anti IL12/23 regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "ustekinumab 45 mg"
            }, 
            {
                "arm_group_label": "Cyclosporine regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "Cyclosporine 2.5-3 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "Psoriasis has been associated with an increasing risk for atherosclerosis. The investigators\n      investigated whether surrogate markers of subclinical atherosclerosis, vascular dysfunction\n      and  myocardial dysfunction are impaired in patients with psoriasis compared to normal\n      controls ,coronary artery disease patients and untreated hypertension subjects. The\n      investigators also examined the effect of treatment with biological vs no biological agents\n      on vascular and LV function in psoriasis."
        }, 
        "brief_title": "Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "The investigators will compare patients with psoriasis with age and sex matched normal\n      controls as well as  patients with angiographically documented CAD and patients with\n      untreated hypertension (HYP) used  as positive control groups\n\n      Patients with psoriasis (PS)  will be randomized to receive an anti-tumor necrosis-a (TNF-a)\n       ,an anti- interleukin 12/23 regimen  or  a cyclosporine regimen.\n\n      The  anti-TNF-agent, Etanercept will be given at a dose  50mg twice weekly for 12 weeks and\n      after then once weekly.\n\n      The  anti-IL12/23 regimen, Ustekinumab will be given at a dose 45 mg at the first visit,  at\n      4 weeks and every 12 weeks if body weight is up to 90 kgr. For body weight >90kgr dose will\n      be adjusted  accordingly.\n\n      Cyclosporine will be administered  at a dose 2.5-3mg/kgr daily.\n\n      At baseline , after 12 weeks and one year of treatment, the investigators will measure:\n\n        1. pulse wave velocity (PWVc) augmentation index (AI) central systolic blood pressure\n           (cSBP) (Complior, Alam Medical and Arteriograph,TensioMed)\n\n        2. flow-mediated dilation of the brachial artery (FMD)\n\n        3. carotid intima-media thickness (IMT) by ultrasonography\n\n        4. coronary flow reserve of the LAD (CFR) by Doppler  echocardiography\n\n        5. E'/A of mitral annular velocities ,LV longitudinal (GLS -%),strain, and strain rate\n           (LongSr-l/s), peak twisting (Tw -deg),peak twisting (Tw-deg/sec)velocity,untwisting at\n           mitral valve opening (unTw) and untwisting (unTw) velocity using speckle tracking\n           echocardiography .\n\n        6. Perfused boundary region (PBR)of the sublingual arterial microvessels (ranged from 5-25\n           microns) using Sideview Darkfield imaging.  (Microscan, Glycocheck) .The PBR in\n           microvessels is the cell-poor layer which results from the phase separation between the\n           flowing red blood cells (RBC) and plasma.The PBR includes the most luminal part of\n           glycocalyx that does allow cell penetration. Increased PBR is considered an accurate\n           index of reduced endothelial glycocalyx thickness because of a deeper RBC penetration\n           in the glycocalyx.\n\n        7. Fetuin serum levels, markers of oxidative stress such as malondialdehyde (MDA) serum\n           levels, protein carbonyls aw well as  thrombosis and inflammation biomarkers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with psoriasis\n\n          -  Age and sex matched patients with CAD, with untreated hypertension and healthy\n             subjects\n\n        Exclusion Criteria:\n\n          -  for psoriasis patients were presence of wall motion abnormalities and ejection\n             fraction \u2264 50%, psoriatic arthritis, history of acute coronary syndrome, familial\n             hyperlipidemia, insulin dependent-diabetes mellitus, chronic obstructive pulmonary\n             disease or asthma, moderate or severe valvular heart disease, primary\n             cardiomyopathies and malignant tumors. CAD was excluded in psoriasis patients by\n             absence of clinical history, angina and reversible myocardial ischemia, as assessed\n             by dobutamine stress echocardiography or thallium scintigraphy\n\n          -  regarding  the group of CAD patients, we only  included patients without history of\n             ST elevation myocardial infarction in order to exclude the presence of transmural\n             scar compromising myocardial function indices. Thus, CAD patients with wall motion\n             abnormalities and ejection fraction of \u2264 50% were excluded. In addition, exclusion\n             criteria, were history of  acute coronary syndrome without ST-segment elevation\n             within the last year, familial hyperlipidemia,  insulin dependent-diabetes mellitus,\n             chronic obstructive pulmonary disease or asthma, moderate or severe valvular heart\n             disease, primary cardiomyopathies and malignant tumor\n\n          -  in normal controls, CAD was excluded by the presence of normal ECG, absence of\n             clinical history and absence of reversible ischemia by means of treadmill test or\n             dobutamine stress echocardiography"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144857", 
            "org_study_id": "213/19-6-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anti-TNFa regimen", 
                "description": "50 mg", 
                "intervention_name": "etanercept", 
                "intervention_type": "Drug", 
                "other_name": "Enbrel"
            }, 
            {
                "arm_group_label": [
                    "Anti IL12/23 regimen", 
                    "Cyclosporine regimen"
                ], 
                "description": "45 mg", 
                "intervention_name": "ustekinumab", 
                "intervention_type": "Drug", 
                "other_name": "Stelara"
            }, 
            {
                "arm_group_label": "Cyclosporine regimen", 
                "description": "Cyclosporine 2.5-3 mg/kgr", 
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug", 
                "other_name": "Neoral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "TNFR-Fc fusion protein"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "email": "ignoik@otenet.gr", 
                "last_name": "Ignatios Ikonomidis, Dr", 
                "phone": "+302105832187"
            }, 
            "facility": {
                "address": {
                    "city": "Athens", 
                    "country": "Greece", 
                    "zip": "12462"
                }, 
                "name": "Attikon Hospital"
            }, 
            "investigator": {
                "last_name": "Ignatios Ikonomidis, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.", 
        "overall_contact": {
            "email": "ignoik@otenet.gr", 
            "last_name": "Ignatios Ikonomidis, Dr", 
            "phone": "2105831264"
        }, 
        "overall_contact_backup": {
            "email": "mvaroudi@gmail.com", 
            "last_name": "Maria Varoudi, Dr", 
            "phone": "6909001116"
        }, 
        "overall_official": {
            "affiliation": "University of Athens", 
            "last_name": "Ignatios Ikonomidis, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a or anti-interleukin 12/23 regimen) with the effects of cyclosporine on endothelial function as assessed by flow mediated dilatation of the brachial artery, coronary flow reserve and endothelial glycocalyx thickness", 
                "measure": "Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on endothelial  function in psoriasis", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a or anti-interleukin 12/23 regimen) with the effects of cyclosporine on vascular function as assessed by pulse wave velocity, augmentation index and central aortic blood pressure,", 
                "measure": "Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on vascular  function in psoriasis", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Comparison of effect (improvement or deterioration) of treatment with biological agents (anti-tumor necrosis factor-a or anti-interleukin 12/23 regimen) with the effects of cyclosporine on cardiac function as assessed by longitudinal myocardial deformation, twisting and untwisting of the left ventricle", 
                "measure": "Comparison of effect (improvement or deterioration) of treatment with biological vs. non biological agents on  cardiac function in psoriasis", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144857"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Athens", 
            "investigator_full_name": "Ignatios Ikonomidis", 
            "investigator_title": "Assistant Professor in Cardiology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Differences in endothelial function between psoriasis and normal controls, and similarities in endothelial function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis .The following parameters will be compared among the study subgroups endothelial function as assessed by flow mediated dilatation of the brachial artery, coronary flow reserve and endothelial glycocalyx thickness", 
                "measure": "Differences and similarities in endothelial function between psoriasis and control groups", 
                "safety_issue": "No", 
                "time_frame": "0 and 12 weeks"
            }, 
            {
                "description": "Differences in vascular  function between psoriasis and normal controls, and similarities in vascular  function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis .The following parameters will be compared among the study subgroups vascular function as assessed by pulse wave velocity, augmentation index and central aortic blood pressure,", 
                "measure": "Differences and similarities in vascular  function between psoriasis and control groups", 
                "safety_issue": "No", 
                "time_frame": "0 and 12 weeks"
            }, 
            {
                "description": "Differences in cardiac function between psoriasis and normal controls, and similarities in  cardiac function between psoriasis and coronary artery disease patients and untreated hypertension patients before and after 4 week of anti-inflammatory treatment in patients with psoriasis The following parameters will be compared among the study subgroups cardiac function as assessed by longitudinal myocardial deformation, twisting and untwisting of the left ventricle", 
                "measure": "Differences and similarities in cardiac function between psoriasis and control groups", 
                "safety_issue": "No", 
                "time_frame": "0 and 12 weeks"
            }
        ], 
        "source": "University of Athens", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Athens", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}